But can you give me a good reason as to why someone would - for years, and years - hang around a MB spewing the same bull over and over and over and over???
I can only think of one good reason, and that is that he got FIRED by the Nigerian CEO.
Oh my god... gregori got canned by a Nigerian goat herder because he got caught with one of the goat herder's GOATS - he swore up and down that his intentions towards the juvenile goat were honorable - but the nigerian goat herder couldn't get over the fact that you had chosen a BILLY GOAT.. and so he CANNED YOU ! ! !
Cheer up gregori - heart breaks like that only hurt for about two or three years - so you're approaching the end of the morning period.
ps - in 3 or 4 years, when IPCI hits 50 bucks a share, I'm going to get me one of those yellow Lamborghini - can't wait.
Well I can't do it - I can't spread mis-information as the AHs on this board do - so in fairness you would have to bring the current share prices to parity for a proper comparison - so if you did a 1 for 6 reverse split on ELTP, the price would be 1.80 and shares outstanding would be ~ 115 million - so they would have to earn $115 Million - still ROFLMFAO
dig a little deeper says - If you have a good reason not to buy ELTP I am all ears.*
How about this - For IPCI to earn $1.00 per share... it has to earn $24 million - easily do-able and SOON.
For ELTP to earn $1.00 per share... READY FOR THIS??? it has to earn $685 Million - YEA - LOL - $685 MILLION
Looking at the yahoo stock chart - what I see is that 178K traded at $2.61 not $2.92 - the $2.92 was a trade at the very end of day for 1K share and it may have been someone who in error keyed in $2.92 rather than $2.62
Don't agree with that at all - I don't think percentage has anything at all to do with market potential - It all has to do with how far along the path to approval the drug is - preclinical gets you 5% to 8 % - successful phase 1 about 10% to 15% - phase 2 , about 15 to 25 % phase 3 = 25 to 35% - FDA approved = 35 to 50% and usually the lower the percentage the bigger the milestone payments. - IPCI would be handing over a ready for market drug with 180 days exclusivity... if they don't get 50% they should get a very hefty up front payment.
If good news does emerge... then whoever bought those shares is in deep do-do - because he/she acted on inside information... and it would be relatively simple to find out who it is.
If I recall right, they did receive $5 million up front, and Novartis bought a couple of million shares of stock
When Will the Generic Be Available?: Some or all forms of Seroquel XR may become available as generic quetiapine xr after November 2016, depending on FDA approval and patent expiration.
I believe IPCI was first to file and has 180 day exclusivity on all 5 strenghts, and I believe this is the drug that they have partnered with TEVA.
p.s. Seroquel XR is a $1.2 BILLION drug - 6 months exclusivity = $600 Million x 60% (40% discount over brand name) = $360 million x 25% market capture during 6 month exclusivity = $90 million x 50% (50/50 split with Teva - most likely) = $45 million divided by 25 million shares = $1.80 earnings per share for 6 months x 20 p/e (reasonable for growing concern) = $36.00 +/- 20% = ~ $28.80 to $43.20 fair value per share... just on Seroquel XR.
Sentiment: Strong Buy